^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PANDA-VAC

    i
    Other names: PANDA-VAC, Personalized and adaptive neoantigen dose-adjusted vaccine
    Associations

    News

    Trials
    Company:
    UNC Lineberger Comprehensive Cancer Center
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    7d
    PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PANDA-VAC
    1year
    PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PANDA-VAC
    almost2years
    PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Oct 2032 --> Jun 2033 | Trial primary completion date: Oct 2022 --> Jun 2023
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PANDA-VAC
    almost3years
    PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Apr 2031 --> Oct 2032 | Trial primary completion date: Apr 2021 --> Oct 2022
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PANDA-VAC
    4years
    PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Initiation date: Feb 2020 --> Sep 2020
    Trial initiation date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PANDA-VAC
    4years
    PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PANDA-VAC